Amarin Corporation Plc ( (AMRN) ) has released its Q4 earnings. Here is a breakdown of the information Amarin Corporation Plc presented to its investors.
Amarin Corporation Plc is a pharmaceutical company specializing in cardiovascular disease management, known for its flagship product VASCEPA/VAZKEPA, which targets high-risk cardiovascular patients. In its latest earnings report, Amarin Corporation announced fourth-quarter 2024 revenues of $62.3 million, with operating expenses of $43.0 million and a year-end cash position of $294.2 million. The company highlighted its strategic focus on expanding the global reach of its VASCEPA/VAZKEPA franchise, securing national reimbursement in Italy and Austria, and launching in new markets such as China and Australia. Despite a 17% decrease in total net revenue compared to the previous year, Amarin reported growth in European and Rest of World markets, while U.S. revenues declined due to generic competition. The company also announced a 1-for-20 ADS ratio change to maintain its Nasdaq listing. Looking ahead, Amarin remains committed to expanding its market presence in Europe and maximizing revenue generation in the U.S. and other regions, with a focus on maintaining financial stability and exploring opportunities to broaden the reach of VASCEPA/VAZKEPA globally.